This article was originally published in April 2009 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
The NTHi hypothesis
Synflorix (PHiD-CV) uses protein D - a cell-surface lipoprotein from Non-Typeable Haemophilus influenzae - as the carrier protein for 8 of its 10 pneumococcal serotypes (serotypes 18C and 19F use tetanus toxoid and diphtheria toxoid respectively). The immunological hypothesis was that this carrier would generate anti-protein D antibodies that could provide partial protection against NTHi ear infections, thereby adding an otitis media benefit beyond Synflorix's pneumococcal coverage. If this hypothesis held clinically, it would represent a genuinely unique product benefit that PCV-13 could not match.
Why otitis media matters commercially
Acute otitis media (AOM) is the most common reason for antibiotic prescription in children under five across developed markets, representing a major source of healthcare costs and parental quality-of-life concern. In European healthcare systems where health technology assessment bodies evaluated vaccine value using cost-effectiveness models, a demonstrated reduction in NTHi-related AOM consultations and antibiotic prescriptions would substantially strengthen Synflorix's cost-effectiveness argument relative to PCV-13.
Estimated proportion of acute otitis media cases attributable to Non-Typeable H. influenzae - the fraction that Synflorix's protein D carrier was designed to target
"The NTHi story is GSK's most powerful commercial weapon against PCV-13 - if the FinIP efficacy data delivers the expected effect size, it will be very difficult for national programmes to justify the premium of PCV-13."